323990 fundamentals
Key facts
Vaxcell-Bio Therapeutics engages in the development of anti-cancer immunotherapy. It operates through the following business divisions: Anticancer Immunotherapy Sector, Pet Healthcare Division, and Distribution Sector including Pharmaceuticals and Medical Supplies. The Anticancer Immunotherapy Sector business division develops an anticancer immunotherapy and is currently in the clinical trial/research stage. The Pet Healthcare business division refers to items from the Goldmun product group. The Distribution Sector including Pharmaceuticals and Medical Supplies business division consists of hunteraze, prolia freefield, innoen levofloxacin injection, albumin, and inoenseftriaxone. The company was founded by Lee Jae-Jung on February 18, 2010 and is headquartered in Hwasun-gun, South Korea.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
Financial health
Financial position and solvency of the company